Rupert Haynes

CEO at Avata Biosciences

Speaker

Rupert is the CEO of Avata Biosciences, where he leads the development of AVAT-021, a treatment for adult focal seizures, targeting a 2028 US launch. Under his leadership, Avata has achieved positive comparative results against Epidiolex, gained FDA support for the 505(b)(2) pathway, and formed a partnership with Oxford University to develop treatments for Schizophrenia. The company is also actively raising $110 million for Phase 3 development. Before Avata, Rupert held senior positions at Radius Health, Benuvia Therapeutics, GW Pharmaceuticals, Sobi, UCB Pharma, and Bristol-Myers Squibb, demonstrating extensive experience in strategic planning, marketing, clinical development, global commercial operations, manufacturing and drug development in the pharmaceutical industry.